Get the Stockscreener App
1.19
0.84%
0.0099
After Hours:
1.19
Barinthus Biotherapeutics Plc Adr stock is traded at $1.19, with a volume of 12,359.
It is up +0.84% in the last 24 hours and down -9.51% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
See More
Previous Close:
$1.1801
Open:
$1.1886
24h Volume:
12,359
Relative Volume:
0.60
Market Cap:
$46.90M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-56.34M
1W Performance:
-0.83%
1M Performance:
-9.51%
6M Performance:
-50.00%
1Y Performance:
+0.00%
1-Day Range:
$1.1886
$1.2456
1-Week Range:
$1.1801
$1.2456
52-Week Range:
$1.11
$4.3898
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
UNIT 6-10, ZEUS BUILDING, DIDCOT
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B - GlobeNewswire Inc.
Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives - Benzinga
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections - GlobeNewswire Inc.
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
TPST Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):